Tempest Therapeutics company info

What does Tempest Therapeutics do?
Tempest Therapeutics (NASDAQ:TPST) is focused on discovering and developing a diverse portfolio of small molecule therapeutics. Their work is dedicated to addressing a wide range of diseases with significant unmet medical needs. Central to their operations are innovative projects aimed at targeting key pathways in cancer biology, immune-oncology, and inflammation. By leveraging cutting-edge science, Tempest aims to advance these therapeutics from conception through clinical development, with the objective of bringing transformative treatments to patients worldwide. Their commitment to research and development underscores a broader mission to improve healthcare outcomes and enhance the quality of life for patients grappling with serious diseases.
Tempest Therapeutics company media
Company Snapshot

Is Tempest Therapeutics a public or private company?


How many people does Tempest Therapeutics employ?


What sector is Tempest Therapeutics in?

pie chart
Health Care

Where is the head office for Tempest Therapeutics?

location pin
Head Office
California, United States

What year was Tempest Therapeutics founded?

founded flag
Year Founded
What does Tempest Therapeutics specialise in?
/Cancer Therapies /Immunotherapy Development /Drug Research /Biological Therapeutics /Clinical Trials /Cancer Research

What are the products and/or services of Tempest Therapeutics?

Overview of Tempest Therapeutics offerings
TPST-1120, a selective PPARa antagonist aimed at treating various cancers by targeting tumor and immune cells.
TPST-1495, a dual EP2/EP4 antagonist for solid tumors, enhancing antitumor immunity.
Preclinical programs focusing on novel targets in immuno-oncology to stimulate the immune system against cancer.
Collaboration projects for the development and commercialization of proprietary oncology therapies.
Research initiatives to identify and validate next-generation targets in cancer therapy.

Who is in the executive team of Tempest Therapeutics?

Tempest Therapeutics leadership team
  • Mr. Stephen R. Brady J.D., LLM
    Mr. Stephen R. Brady J.D., LLM
    CEO, President & Director
  • Dr. Samuel  Whiting M.D., Ph.D.
    Dr. Samuel Whiting M.D., Ph.D.
    Executive VP & Chief Medical Officer
  • Mr. Nicholas  Maestas
    Mr. Nicholas Maestas
    VP of Strategy & Finance and Secretary
  • Mr. Justin  Trojanowski
    Mr. Justin Trojanowski
    Corporate Controller, Treasurer & Principal Accounting Officer
  • Ms. Lindsay  Young
    Ms. Lindsay Young
    Head of Human Resources
  • Dr. Sharon  Sakai Ph.D., RAC
    Dr. Sharon Sakai Ph.D., RAC
    Head of Regulatory & Quality